Amylyx initiated with a Buy at Mizuho

Mizuho analyst Graig Suvannavejh initiated coverage of Amylyx with a Buy rating and $52 price target. The neurology-focused company markets AMX0035, branded as Relyvrio in the U.S., for amyotrophic lateral sclerosis, or ALS and the firm’s proprietary checks with experts and survey work "supports heavy Relyvrio usage," the analyst tells investors. The firm’s estimates are above consensus on AMX0035’s near and longer-term outlook, Mizuho noted.